Login to Your Account



Rib-X Files for $80M IPO as Lead Antibiotic Nears Phase III

By Trista Morrison
Staff Writer

Tuesday, November 29, 2011
With Phase IIb data for antibiotic delafloxacin expected by the end of the year and a Phase III trial slated to start in 2012, Rib-X Pharmaceuticals Inc. moved to bolster its balance sheet by raising up to $80 million in an initial public offering.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription